Recent studies have focused on the overlap of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and dopamine communication. While GLP stimulators are commonly employed for treating type 2 T2DM, their unexpected consequences on motivation circuits, specifically mediated by DA networks, are receiving consid